We assessed the accuracy of the Centers for Disease Control and Prevention (CDC) clinical criteria as well as other microbiological methods for the diagnosis of coagulase-negative staphylococci bacteraemia. The CDC clinical criteria had low accuracy, which can be improved by speciation, particularly if the patient had more than two positive blood cultures.
Coagulase-negative staphylococci (CoNS) are the most common cause of health care-associated bloodstream infections [1, 2] , partly because of the increased use of indwelling medical devices, such as central venous catheters and other prosthetic materials [3, 4] . However, CoNS are also common colonizers of human skin; hence, a positive blood culture for CoNS may represent contamination [5] . To avoid unnecessary catheter removal and the inappropriate use of empiric antibiotics, it is important to differentiate CoNS bacteraemia from contamination [6, 7] . Several studies evaluated CDC clinical criteria and showed that they correlate poorly with genotyping, suggesting that they are an inaccurate diagnostic method [5, 8] . However, the routine use of molecular techniques may impose a prohibitive cost for some laboratories. Alternative and inexpensive diagnostic techniques are needed. We evaluated the accuracy of the CDC clinical criteria and other microbiological methods (e.g. species identification) when diagnosing CoNS bacteraemia in cancer patients using molecular genotype matching.
This retrospective study was performed at M. D. Anderson Cancer Center between January 2006 and May 2008. All patients with two or more positive blood culture sets for CoNS within a one-week period were eligible, and their medical records were reviewed. We determined species specification and genotype on available paired samples (the first two cultures).
Clinical data collected included age, sex, underlying disease, symptoms of infection, microbiological data, other infection sites, and exposure to antibiotic therapy. Patients with polymicrobial cultures were excluded.
The clinical definition of CoNS bacteraemia was based on the CDC's criterion [9] of ‡2 positive blood cultures within 48 h, along with symptoms of infection (i.e. fever >38, chills, or hypotension) that are not related to another infection. Patients were considered to have true CoNS bacteraemia if they met the CDC clinical criteria and if identical species and strains were isolated from positive blood culture sets. New CDC criteria also add same antibiograms of isolates (http://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_ clabscurrent.pdf).
We identified the bacterial strains using the VITEKI GPIV1305 automatic identification system (BioMerieux, Marcy l'Etoile, France). CoNS strains were identified by gram stain morphology, catalase positivity, staphAurex and tube coagulation. The CoNS microbial genotype was determined using the repetitive polymerase chain reaction (PCR) method with the DiversiLab repetitive-PCR genotyping system (Spectral Genomics, Houston, TX, USA). DNA was extracted from an overnight culture with the UltraClean DNA isolation kit (Mo Bio Laboratories Inc., Carlsbad, CA, USA). Bacterial DNA was amplified using a Gene Amp PCR system 9700 (Applied Biosystems, Foster City, CA, USA) with the DiversiLab Staphylococcus PCR reaction mix, which contains manufacturer-supplied primers for Staphylococcus strains. PCR products were loaded on a microfluid device containing a fluorescent DNA intercalating dye. The DNA fragments were separated within micro-channels by electrophoresis on the basis of size and detected using a laser beam. The data were reported as a dendogram and similarity matrix, which were used to interpret the data. We used 16sPCR and sequencing to confirm the results of indeterminate cases by VITEKI.
We compared the sensitivity, specificity, positive and negative predictive values of the CDC clinical criteria and species identification, separately and combined, using molecular genotyping as the reference standard. We also estimated the 95% confidence interval for the calculated sensitivity and specificity. We compared clinical and microbiological features between identical and different pairs using chi-square for bivariate analysis and built logistic regression model, including all variables with a p value for association with identical genotype of 0.25 or less. All statistical tests were two tailed with a level of significance of £0.05. SAS, version 9 (SAS, Cary, NC, USA) was used for all statistical analyses.
From January 2006 to May 2008 we identified 101 patients with at least two CoNS-positive blood cultures with available isolates. Most of the patients (90%) fulfilled the CDC's clinical criteria for bloodstream infection. Most isolate pairs (73.2%) had identical genotypes, whereas 26.7% were different ( Table 1 ).
The sensitivity of the CDC clinical criteria was 91%, but its specificity was only 11%. On the other hand, species identification had a sensitivity of 100% and a specificity of 48% ( Table 2 ). The sensitivity and specificity of the CDC clinical criteria and species identification combined were 91% and 52%, respectively, with a PPV of 84% and NPV of 67%. The new CDC criteria had a sensitivity of 76%, specificity of 26%, PPV of 75% and NPV of 27%. Staphylococcus epidermidis was the most common (86.13%) followed by Staphylococcus hominis (5.94%). Most patients (98%) had a CVC in place at the time of bacteraemia.
By multivariate analysis, patients with identical genotypes were more likely to have more than two positive blood culture sets (55.4% vs. 29.6%; p 0.02), although, by univariate analysis, patients with the same genotypes were more likely to have an interval between the two blood culture sets <72 h (18.5% vs. 5.4%; p 0.05). However, this difference was not statistically significant by multivariate analysis. No other variables differed significantly between the two groups ( Table 1) .
Both CDC clinical criteria are sensitive for the primary diagnosis of CoNS bacteraemia; however, in our study, many patients met the CDC clinical criteria but had genotypically different isolated bacterial strains. Seo et al. [10] and Senger et al. [11] found that the CDC clinical criteria correlated poorly with molecular genotyping. Thus, based on our data, we recommend using the CDC clinical criteria as a screening test for bloodstream infections rather than as the ultimate confirmatory test in the setting of multiple CoNS-positive blood cultures sets.
Species identification is a simple and quick diagnostic technique, but it cannot always establish a final diagnosis of CoNS bacteraemia when used alone. The combination of the CDC clinical criteria and species identification was associated with higher diagnostic accuracy than either alone, but its specificity remained low. The limitations of molecular genotyping are that it is costly, time consuming, and available only in advanced research centres. If patients had more than two positive blood culture sets for CoNS they were more likely to have a true genotypically proven bacteraemia by univariate and multivariate analysis. García [12] showed that patients with two or more blood cultures positive for CoNS were more likely to have true bacteraemia than those with only one; however, Seybold et al. [13] showed that even two consecutive cultures may represent contamination. Consequently, having more than two positive cultures may be a good predictor for CoNS bloodstream infection.
In conclusion, to confirm the diagnosis of CoNS bacteraemia, it is prudent for clinicians to use the CDC clinical criteria along with species identification. These combined methods are less accurate than molecular genotyping [10, 11] , yet they are rapid and available in most hospitals, and may guide physicians in determining the right treatment plan. More than two positive blood culture sets, if available, may further confirm the diagnosis.
